Evidence map›Paper›PMID 40225810›Full record

ReviewDrugs in context2025

Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008-2024) and pipeline phase III medications.

Emile Tadros, Shirley Keerthana, Samar Padder, Jayant Totlani, Drew Hirsch, Daniel N Kaidbay, Lorena Contreras, Aasim Naqvi, Samuel Miles, Krista Mercado and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drugs in context, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Anxiety disorders: a cross-sectional study of clinical and biological associations.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Emile Tadros *Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Shirley Keerthana *Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Samar Padder *Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jayant Totlani *Virginia Commonwealth University Health System, Richmond, VA, USA.
Drew Hirsch *Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Daniel N Kaidbay *Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Lorena Contreras *Keck Medicine of University of Southern California, Los Angeles, CA, USA.
Aasim Naqvi *Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Samuel Miles *Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Krista Mercado *University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Ashley Meyer *University of California Irvine School of Medicine, Irvine, CA, USA.
Sabrina Renteria *Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Robert N Pechnick *Western University of Health Sciences, Pomona, CA, USA.
Itai Danovitch *Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Waguih William IsHak *Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This systematic review examines psychiatric medications approved by the FDA for anxiety disorders, post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD) from 2008 to 2024 and describes the mechanism of action, indications for both labelled and off-label uses, evidence for efficacy, dosing and adverse effects for each medication. Methods: The methodology involved a literature search of the PubMed database for studies published from 1 January 2008 to 31 December 2024 on FDA-approved psychiatric medications and phase III pipeline medications, using the keywords: "anxiety" OR "PTSD" OR "OCD" AND "psychopharm*" OR "medic*" OR "pharm*". The authors conducted independent assessments of the resulting articles and reached a consensus on eligible studies to include in this systematic review. Results: Our review revealed that, in the past 16 years, the FDA approved only two medications for anxiety disorders (a delayed-release form of duloxetine for generalized anxiety disorder and an extended-release form of lorazepam) and none for PTSD or OCD. We also identified 14 pipeline medications for anxiety disorders, eight for PTSD and one for OCD, all of which are currently in phase III clinical trials. Conclusion: Our results showed a paucity of new medications for anxiety disorders and none for PTSD and OCD in the past 16 years. However, phase III psychiatric medications for anxiety disorders, PTSD and OCD seem to show several agents with novel mechanisms of action, various modes of administration, and improved side-effect profiles.

Indexed as

anxiety disordersFDA-approvedOCDpsychiatric disorderspsychiatric medicationsPTSD

Identifiers

PMID40225810
PMCPMC11991790

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.